Top News
Celltrion Launches Xolair Biosimilar Omlyclo in U.S. for Hives and Asthma
Celltrion has launched Omlyclo, the first omalizumab biosimilar in the U.S., for chronic spontaneous urticaria and allergic asthma, with preferred formulary placement from major pharmacy benefit manager Optum.
- Our Sponsors Ad -